07:00 , Apr 23, 2007 |  BioCentury  |  Finance

Ebb & Flow

Gilead (GILD) gave the Street another upside surprise for the first quarter, but the EPS uplift looks to have come from less spending on R&D, rather than unexpectedly high revenue. Indeed, while GILD's quarterly revenue...
00:40 , Apr 20, 2007 |  BC Extra  |  Financial News

Metabolex raises $32 million

Metabolex (Hayward, Calif.) raised $32 million in a series D round led by MPM Capital. New investors AllianceBernstein, Deerfield Capital Management and T. Rowe Price joined existing investors Alta Partners, Bay City Capital, Biotech Turnaround...
08:00 , Dec 6, 2004 |  BioCentury  |  Finance

Ebb & Flow Focus

Although Metabolex hasn't done a financing with a valuation step-up in more than two years, the company's story drives home the point that valuation takes a back seat to survival. The diabetes company, which was...
07:00 , Sep 1, 2003 |  BC Week In Review  |  Company News

Metabolex board of directors update

Metabolex Inc. , Hayward, Calif.   Business: Metabolic   Appointed: Carl Goldfischer, managing director of Bay City Capital; Sylvain Gareau, partner at CDP Capital Technology Ventures; Jan Drayer, pharmaceutical consultant to Biotech Turnaround Fund; and...
07:00 , Sep 1, 2003 |  BioCentury  |  Finance

Ebb & Flow

A horse kept in the stable too long can turn a measured trot into a mad sprint. Not one IPO has gotten done yet, but 10 companies are already in the queue, with about $800...
07:00 , Aug 27, 2003 |  BC Extra  |  Financial News

Metabolex raises $27 million

Metabolic company Metabolex (Hayward, Calif.) raised $27 million in a private round led by Bay City Capital; Biotech Turnaround Fund; and CDP Capital Technology Ventures. Other investors included Charter Ventures and KBC. CIBC acted as...